Aging impacts CAR T cell therapy at multiple levels, from manufacturing to therapeutic efficacy biorxiv.org/content/10.110…

Stunning. With rollout of the RSV vaccine and treatment for babies <8 months old, RSV hospitalizations fell >50%. By comparison, for toddlers and kids <5 years who were not covered by these advances, RSV hospitalizations did not fall.

CAR T cell therapy can cause cognitive impairment via persistent neuroinflammation that disrupts oligodendroglial homeostasis & hippocampal neurogenesis. This can be rescued by microglial depletion or CCR3 blockade. Cell Michelle Monje🎗️ 🟦 cell.com/cell/fulltext/…

Biologics and T-cell Engagers: Researchers shared updates on cutting-edge immunotherapies during this #AACR25 Clinical Trials Plenary Session. Read a recap in AACR Annual Meeting News: brnw.ch/21wSCNn Juan C Osorio MD

With a Pneumothorax rate of 3.3% in the navigational bronchoscopy group & 28.3% in the transthoracic biopsy group, Navigational bronch might be new standard of care. The diagnostic accuracy of #navigationalbronchoscopy was noninferior to that of transthoracic needle biopsy

For readers interested in CAR-T cell therapies in cancer immunotherapy, this Review in the May issue discusses management of toxicities and reviews druggable targets and cellular engineering strategies to develop safer CAR-T cells nature.com/articles/s4157… rdcu.be/em0rW

New #JITC article: Associations between immune checkpoint inhibitor response, immune-related adverse events, and steroid use in RADIOHEAD: a prospective pan-tumor cohort study bit.ly/4dpztXb John Connolly

CAR-NK’s balancing act: when scFv affinity is not too tight, not too loose… but just right? jitc.bmj.com/content/13/5/e…

🔬 Science Spotlight at Fred Hutch Cancer Center: A real-world, 3-year analysis compares axi-cel & liso-cel for relapsed LBCL. Both CAR-T therapies were equally effective, but liso-cel had less CRS, ICANS, & supportive care. 🔗fredhutch.org/en/news/spotli… 📄haematologica.org/article/view/1… Jordan Gauthier

#mmsm #ASCO25 Journal of Clinical Oncology Long term CARTITUDE-1 data published One out of 3 of patients treated with Cilta cel alive and disease free 5 years after ttt (tail of the curve)👇 Details of deaths 👇 and timing ascopubs.org/doi/full/10.12…

Presented at #ADASciSessions: Zimislecel is an allogeneic stem cell–derived islet-cell therapy. This phase 1–2 study supports the hypothesis that zimislecel can restore physiologic islet function and thus treat persons with type 1 diabetes. Full study: nej.md/3ZGupbv

Beautiful paper by my good friend Philipp Karschnia, amazing to see all your academic progress in the last decade! Highly recommended reading out in Nat Rev Neurology on all things CAR-T neurotoxicity - from ICANS to TIAN and MNTs👇

🚨 New in Nature Medicine: “Noncanonical and mortality-defining toxicities of CAR T cell therapy” As CAR-T moves beyond heme malignancies, we need a deeper understanding of rare & long-term toxicities. 🔗 nature.com/articles/s4159… PDF: rdcu.be/ewqLH

🚨🚨Phase 2 trial on itacitinib for CRS/ICANS prevention in CAR T-cell therapy Highly recommended to read as this could be applicable for CAR-T in myeloma and BiTes as well 🧵1/ Groundbreaking update in CAR T-cell therapy: Can we prevent CRS and ICANS, rather than just react

Breakthrough study: COVID-19 reactivates dormant breast cancer, triggering deadly metastasis (shown in mice). In humans, cancer survivors who got COVID had 4.5× higher cancer-related deaths—and 1.4× greater breast cancer. nature.com/articles/s4158…

Comparative Efficacy of Bendamustine Versus Fludarabine/Cyclophosphamide for Lymphodepletion Before Chimeric Antigen Receptor T-Cell Therapy in Lymphoma Transplantation and Cellular Therapy Journal astctjournal.org/article/S2666-…

T cell are critical for anti-tumor immunity reprogramming by radiotherapy, but tumor cell derived protein C receptor-driven IL-6 inhibits this nature.com/articles/s4146… Nature Communications

🆕🗞️Hot off the press! Nature Medicine #KRAS Vaccine💉for patients with RAS➕cancers🎯. Benefit➡️durable.🙌🏽 More to come with the randomized study📚✔️! Opens to doors to off the shelf vaccine for so many patients with KRAS/NRAS mutations. OncoAlert 🔗nature.com/articles/s4159…

A major win for solid tumors; GD2 #CART mediated a 40% complete remission rate in children with high-risk neuroblastoma Nature Medicine ! nature.com/articles/s4159…

Is your center allowing for BCMA CAR T-cell therapy in patients with myeloma on dialysis for renal failure? We describe our early experience with ide-cel/cilta-cel in patients on dialysis. Bottom line: - Don't let ESKD be a barrier! - Reducing fludarabine + dialyzing each day